A phase 1/pharmacokinetic study of sunitinib in combination with highly active antiretroviral therapy in human immunodeficiency virus-positive patients with cancer: AIDS Malignancy Consortium trial AMC 061

By Rudek Michelle A.   Moore Page C.   Mitsuyasu Ronald T.   Dezube Bruce J.   Aboulafia David   Gerecitano John   Sullivan Ryan   Cianfrocca Mary E.   Henry David H.   Ratner Lee   Haigentz Missak   Dowlati Afshin   Little Richard F.   Ivy Susan Percy   Deeken John F.  

Cancer, Vol. 120, Iss. 8, 2014-04 ,pp. : 1194-1202

Blackwell Publishing

Access to resources Recommend Favorite

Treatment of Posterior Cheek Enlargement in Human Immunodeficiency Virus-positive Individuals with Botulinum Toxin A

By Scali Christina   Humphrey Shannon   Jones Derek   Carruthers Alastair  

Dermatologic Surgery, Vol. 39, Iss. 9, 2013-09 ,pp. : 1407-1410

Elsevier

Access to resources Recommend Favorite

Targeting frameshifting in the human immunodeficiency virus

By Brakier-Gingras Léa   Charbonneau Johanie   Butcher Samuel E  

Expert Opinion on Therapeutic Targets, Vol. 16, Iss. 3, 2012-03 ,pp. : 249-258

Informa Healthcare

Access to resources Recommend Favorite

A Pharmacokinetic–Pharmacodynamic Model of Chemotherapy of Human Immunodeficiency Virus Infection that Relates Development of Drug Resistance to Treatment Intensity

By Jackson Robert C.  

Journal of Pharmacokinetics and Pharmacodynamics, Vol. 25, Iss. 6, 1997-12 ,pp. : 713-730

Springer Publishing Company

Access to resources Recommend Favorite

Lopinavir/ritonavir in the treatment of human immunodeficiency virus infection

By Kaplan Susan S   Hicks Charles B  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 9, 2005-08 ,pp. : 1573-1585

Informa Healthcare

Access to resources Recommend Favorite